JP2007529204A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007529204A5 JP2007529204A5 JP2007503106A JP2007503106A JP2007529204A5 JP 2007529204 A5 JP2007529204 A5 JP 2007529204A5 JP 2007503106 A JP2007503106 A JP 2007503106A JP 2007503106 A JP2007503106 A JP 2007503106A JP 2007529204 A5 JP2007529204 A5 JP 2007529204A5
- Authority
- JP
- Japan
- Prior art keywords
- tim
- seq
- polypeptide
- amino acid
- amino acids
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001184 polypeptide Polymers 0.000 claims 29
- 102000004196 processed proteins & peptides Human genes 0.000 claims 29
- 108090000765 processed proteins & peptides Proteins 0.000 claims 29
- 150000001413 amino acids Chemical class 0.000 claims 16
- 101100369802 Caenorhabditis elegans tim-1 gene Proteins 0.000 claims 13
- 125000003275 alpha amino acid group Chemical group 0.000 claims 10
- 239000003795 chemical substances by application Substances 0.000 claims 10
- 230000000069 prophylactic effect Effects 0.000 claims 8
- 230000001225 therapeutic effect Effects 0.000 claims 8
- 230000000694 effects Effects 0.000 claims 5
- 210000001744 T-lymphocyte Anatomy 0.000 claims 4
- 230000003321 amplification Effects 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 230000001404 mediated effect Effects 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 238000003199 nucleic acid amplification method Methods 0.000 claims 4
- 230000015572 biosynthetic process Effects 0.000 claims 3
- 125000000539 amino acid group Chemical group 0.000 claims 2
- 230000003834 intracellular effect Effects 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 208000012657 Atopic disease Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 230000029662 T-helper 1 type immune response Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 208000005252 hepatitis A Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55252304P | 2004-03-12 | 2004-03-12 | |
| US60/552,523 | 2004-03-12 | ||
| US62255904P | 2004-10-27 | 2004-10-27 | |
| US60/622,559 | 2004-10-27 | ||
| PCT/US2005/008423 WO2005090573A2 (en) | 2004-03-12 | 2005-03-14 | Methods of modulating immune responses by modulating tim-1, tim-2 and tim-4 function |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011255899A Division JP2012070749A (ja) | 2004-03-12 | 2011-11-24 | Ｔｉｍ−１、ｔｉｍ−２、およびｔｉｍ−４の機能を調節することによって免疫応答を調節する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007529204A JP2007529204A (ja) | 2007-10-25 |
| JP2007529204A5 true JP2007529204A5 (enExample) | 2008-05-01 |
| JP4903128B2 JP4903128B2 (ja) | 2012-03-28 |
Family
ID=34994427
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007503106A Expired - Fee Related JP4903128B2 (ja) | 2004-03-12 | 2005-03-14 | Ｔｉｍ−１、ｔｉｍ−２、およびｔｉｍ−４の機能を調節することによって免疫応答を調節する方法 |
| JP2011255899A Pending JP2012070749A (ja) | 2004-03-12 | 2011-11-24 | Ｔｉｍ−１、ｔｉｍ−２、およびｔｉｍ−４の機能を調節することによって免疫応答を調節する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011255899A Pending JP2012070749A (ja) | 2004-03-12 | 2011-11-24 | Ｔｉｍ−１、ｔｉｍ−２、およびｔｉｍ−４の機能を調節することによって免疫応答を調節する方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US7741271B2 (enExample) |
| EP (1) | EP1735445B1 (enExample) |
| JP (2) | JP4903128B2 (enExample) |
| KR (1) | KR20060130731A (enExample) |
| CN (1) | CN102861319A (enExample) |
| AU (1) | AU2005224634A1 (enExample) |
| BR (1) | BRPI0508553A (enExample) |
| CA (1) | CA2558371C (enExample) |
| IL (1) | IL178002A (enExample) |
| MX (1) | MXPA06010419A (enExample) |
| RU (1) | RU2006136011A (enExample) |
| TW (1) | TW200539890A (enExample) |
| WO (1) | WO2005090573A2 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SK285461B6 (sk) * | 1996-05-24 | 2007-02-01 | Biogen Idec Ma Inc. | Izolovaný polypeptid KIM, modulátor tkanivovej regenerácie a nukleová kyselina, ktorá ho kóduje, spôsob prípravy polypeptidu a farmaceutická kompozícia obsahujúca polypeptid |
| CN1835769B (zh) * | 2002-12-30 | 2011-06-29 | 比奥根艾迪克Ma公司 | Kim-1拮抗剂及其在免疫系统调节中的应用 |
| BRPI0509139A (pt) * | 2004-03-24 | 2007-08-28 | Telos Fharmaceuticals Inc | composição, e, método de estimulação de uma resposta imune em um indivìduo, de tratamento profilático de uma doença, de melhoramento de um sinal ou sintoma associado com uma doença, de alvejamento de um tumor, de inibição do crescimento de tumor, e de detecção de um tumor |
| EP1865985B1 (en) * | 2005-03-02 | 2010-08-25 | Biogen Idec MA Inc. | Kim-1 antibodies for treatment of th2-mediated conditions |
| WO2007101254A2 (en) * | 2006-02-28 | 2007-09-07 | Telos Pharmaceuticals Llc | Compositions and methods for the treatment of immune system disorders |
| WO2009064290A1 (en) * | 2007-11-13 | 2009-05-22 | Government Of The United States As Represented By The Secretary Of The Department Of Health And Human Services | Structure of tim family members |
| US9758794B2 (en) | 2008-04-22 | 2017-09-12 | Rutgers, The State University Of New Jersey | HCV E2 construct compositions and methods |
| WO2009131572A1 (en) * | 2008-04-22 | 2009-10-29 | Government Of The U.S. As Represented By The Secretary Of The Department Of Health And Human Service | Structure of tim family members |
| CA2722423A1 (en) * | 2008-04-22 | 2009-10-29 | Rutgers, The State University | Hcv e2 construct compositions and methods |
| JP6124261B2 (ja) * | 2011-11-21 | 2017-05-10 | 国立大学法人 筑波大学 | 活性調節剤、これを含有する医薬品、および抗ＣＤ３００ａ抗体 |
| JP6226333B2 (ja) | 2012-11-07 | 2017-11-08 | 国立大学法人 筑波大学 | アレルギー疾患に関連する、ＣＤ３００ａ発現細胞の活性調節剤を含有する医薬品、ならびにＣＤ３００ａ遺伝子欠損マウスおよびＣＤ３００ａ発現細胞の活性調節剤の使用 |
| US9651561B2 (en) | 2012-11-20 | 2017-05-16 | The Brigham And Womens's Hospital, Inc. | Diagnosis and treatment of endometriosis and related conditions |
| KR101510742B1 (ko) | 2013-05-13 | 2015-04-10 | (주)케어젠 | 비만세포―특이적 아팝토시스-유도용 펩타이드 및 이의 용도 |
| WO2015187541A1 (en) * | 2014-06-02 | 2015-12-10 | Children's Medical Center Corporation | Methods and compositions for immunomodulation |
| JP7187151B2 (ja) * | 2015-04-10 | 2022-12-12 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 生存細胞の画像解析のための方法及び装置 |
| US20180153986A1 (en) * | 2015-04-24 | 2018-06-07 | The Brigham And Women's Hospital, Inc. | Interactions between ceacam and tim family members |
| US20170328919A1 (en) * | 2016-05-11 | 2017-11-16 | Leuvas Therapeutics | BLOCKADE OF TIM-1 PATHWAYS and P-SELECTIN PATHWAYS IN TREATMENT OF NEUROINFLAMMATORY DEGENERATIVE DISEASE |
| EP3481866B1 (en) | 2016-07-06 | 2024-07-24 | Bristol-Myers Squibb Company | Combination of tim-4 antagonist and pd-1 antagonist and methods of use |
| CA3035080A1 (en) | 2016-09-27 | 2018-04-05 | Cero Therapeutics, Inc. | Chimeric engulfment receptor molecules |
| AU2018251839B2 (en) * | 2017-04-10 | 2022-06-30 | Immatics Biotechnologies Gmbh | Peptides and combination thereof for use in the immunotherapy against cancers |
| US11365228B2 (en) | 2017-07-06 | 2022-06-21 | Yale University | Mutant FGF21 polypeptide compositions |
| JP7286658B2 (ja) | 2017-09-26 | 2023-06-05 | セロ・セラピューティクス・インコーポレイテッド | キメラエンガルフメント受容体分子および使用方法 |
| WO2019118620A1 (en) * | 2017-12-13 | 2019-06-20 | Yale University | Compositions and methods for treating or preventing endocrine fgf23-linked diseases |
| AU2019243154A1 (en) | 2018-03-28 | 2020-10-01 | Cero Therapeutics, Inc. | Cellular immunotherapy compositions and uses thereof |
| EP3774906A1 (en) | 2018-03-28 | 2021-02-17 | Cero Therapeutics, Inc. | Chimeric tim4 receptors and uses thereof |
| US20240191192A1 (en) * | 2021-04-08 | 2024-06-13 | Takeda Pharmaceutical Company Limited | Method for activating t-cells |
| WO2025064933A1 (en) * | 2023-09-22 | 2025-03-27 | The Trustees Of Columbia University In The City Of New York | Restoring tim4 in liver macrophages to treat non-alcoholic steatohepatitis (nash) |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6066322A (en) | 1995-03-03 | 2000-05-23 | Millennium Pharmaceuticals, Inc. | Methods for the treatment of immune disorders |
| US20030069196A1 (en) | 1995-03-03 | 2003-04-10 | Millennium Pharmaceuticals, Inc. | Compositions and methods for the treatment and diagnosis of immune disorders |
| US6455685B1 (en) | 1995-03-03 | 2002-09-24 | Millennium Pharmaceuticals, Inc. | Compositions and methods for the treatment and diagnosis of immune disorders |
| US6027916A (en) | 1996-10-09 | 2000-02-22 | Human Genome Sciences, Inc. | Galectin 9 and 10SV Polynucleotides |
| EP1012266A4 (en) | 1996-10-09 | 2004-04-28 | Human Genome Sciences Inc | GALECTINE 8, 9, 10, AND 10SV |
| US6190909B1 (en) | 1997-04-17 | 2001-02-20 | Millennium Pharmaceuticals, Inc. | TH2-specific gene |
| WO1999033990A1 (en) * | 1997-12-30 | 1999-07-08 | Chiron Corporation | HUMAN CXC CHEMOKINE (Tim-1) |
| AU2451199A (en) * | 1998-01-07 | 1999-07-26 | Human Genome Sciences, Inc. | 36 human secreted proteins |
| WO2001057188A2 (en) * | 2000-02-03 | 2001-08-09 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
| WO2001055309A2 (en) | 2000-01-31 | 2001-08-02 | Human Genome Sciences, Inc. | Nucleic acids, proteins, and antibodies |
| CA2402211A1 (en) * | 2000-03-08 | 2001-09-13 | National Jewish Medical And Research Center | Phosphatidyl serine receptors and uses thereof |
| WO2002081517A2 (en) | 2001-01-19 | 2002-10-17 | Curagen Corporation | Novel polypeptides and nucleic acids encoded thereby |
| NZ530451A (en) * | 2001-06-29 | 2008-04-30 | Univ Leland Stanford Junior | TIM gene sequences and their use in immunological disorders and cancer |
| US7838220B2 (en) * | 2001-06-29 | 2010-11-23 | The Board Of Trustees Of The Leland Stanford Junior University | T cell regulatory genes associated with immune disease |
| EP3020413A1 (en) | 2002-01-30 | 2016-05-18 | The Brigham and Women's Hospital, Inc. | Compositions and methods related to TIM-3, a TH1-specific cell surface molecule |
| DE10213762A1 (de) * | 2002-03-26 | 2003-10-09 | Boehringer Ingelheim Int | Neues costimulierendes Molekül und dessen Verwendung |
| CN1835769B (zh) | 2002-12-30 | 2011-06-29 | 比奥根艾迪克Ma公司 | Kim-1拮抗剂及其在免疫系统调节中的应用 |
| MXPA06003686A (es) * | 2003-10-03 | 2007-03-01 | Brigham & Womens Hospital | Ligandos tim-3 y sus metodos. |
| BRPI0509139A (pt) * | 2004-03-24 | 2007-08-28 | Telos Fharmaceuticals Inc | composição, e, método de estimulação de uma resposta imune em um indivìduo, de tratamento profilático de uma doença, de melhoramento de um sinal ou sintoma associado com uma doença, de alvejamento de um tumor, de inibição do crescimento de tumor, e de detecção de um tumor |
-
2005
- 2005-03-11 TW TW094107611A patent/TW200539890A/zh unknown
- 2005-03-14 JP JP2007503106A patent/JP4903128B2/ja not_active Expired - Fee Related
- 2005-03-14 AU AU2005224634A patent/AU2005224634A1/en not_active Abandoned
- 2005-03-14 MX MXPA06010419A patent/MXPA06010419A/es not_active Application Discontinuation
- 2005-03-14 BR BRPI0508553-5A patent/BRPI0508553A/pt not_active IP Right Cessation
- 2005-03-14 CN CN2012100590620A patent/CN102861319A/zh active Pending
- 2005-03-14 KR KR1020067021139A patent/KR20060130731A/ko not_active Withdrawn
- 2005-03-14 CA CA2558371A patent/CA2558371C/en not_active Expired - Fee Related
- 2005-03-14 EP EP05732272.9A patent/EP1735445B1/en not_active Expired - Lifetime
- 2005-03-14 US US11/080,091 patent/US7741271B2/en not_active Expired - Lifetime
- 2005-03-14 WO PCT/US2005/008423 patent/WO2005090573A2/en not_active Ceased
- 2005-03-14 RU RU2006136011/13A patent/RU2006136011A/ru not_active Application Discontinuation
-
2006
- 2006-09-11 IL IL178002A patent/IL178002A/en not_active IP Right Cessation
-
2010
- 2010-04-26 US US12/767,434 patent/US20110045002A1/en not_active Abandoned
-
2011
- 2011-11-24 JP JP2011255899A patent/JP2012070749A/ja active Pending
-
2013
- 2013-01-25 US US13/750,092 patent/US20130195895A1/en not_active Abandoned
-
2014
- 2014-10-01 US US14/503,768 patent/US20150079085A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007529204A5 (enExample) | ||
| NZ606427A (en) | Extended recombinant polypeptides and compositions comprising same | |
| JP2015525217A5 (enExample) | ||
| JP2018532382A5 (enExample) | ||
| JP2010519176A5 (enExample) | ||
| JP2010519252A5 (enExample) | ||
| NZ604818A (en) | Variants of activin iib receptor polypeptides and uses thereof | |
| JP2013527765A5 (enExample) | ||
| HRP20161458T1 (hr) | Polipeptidi, polinukleotidi i pripravci namijenjeni upotrebi u liječenju latentne tuberkuloze | |
| JP2011528895A5 (enExample) | ||
| JP2013517783A5 (enExample) | ||
| JP2019525753A5 (enExample) | ||
| JP2015510393A5 (enExample) | ||
| NZ609216A (en) | Anticancer fusion protein | |
| JP2011509093A5 (enExample) | ||
| JP2008530975A5 (enExample) | ||
| JP2004536585A5 (enExample) | ||
| HRP20171694T1 (hr) | Novi pripravci i postupci | |
| JP2014529399A5 (enExample) | ||
| JP2006506942A5 (enExample) | ||
| JP2009545526A5 (enExample) | ||
| JP2008538923A5 (enExample) | ||
| JP2010528584A5 (enExample) | ||
| JP2008521795A5 (enExample) | ||
| RU2012136464A (ru) | Модифицированные пептиды melk и содержащие их вакцины |